Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.00, read 2026-11-05
Ethical passes the values gate
Price45.47 USD
Fair value39.86
Ethical score70.0/100
Value readOvervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-10-28Read Markup40.35+12.7% to today ✓Distribution gives way to Markup first Markup read since August
2026-10-27Read Distribution40.35+12.7% to today Markdown gives way to Distribution first Distribution read since July
2026-09-24Read Markdown40.44+12.4% to today Markup gives way to Markdown after an 11% slide in 5 weeks
2026-08-22Read Markup45.69-0.5% to today Distribution gives way to Markup after a 21% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Avient Corporation holds its Markup at $45.47. Consolidating, no directional conviction, held for 40 days.
As held on the ledger · 2026-11-06
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 40 days
Price at the screen
$45.47
Valuation
25.87 trailing · 13.61 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.25
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.20%
Below 33%
Interest-bearing debt is just 33.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
15.69%
Below 49%
Money owed to the company is 15.7% of assets, under the 49% limit.
Pass
Revenue purity
1.42%
Below 5%
Only 1.4% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Avient clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 33%, inside the ~33% line, and interest is about 1% of its income, under the ~5% line, so it passes.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when AVNT's ethical verdict changes
Today AVNT passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 6 Nov 2026: it trades above our $39.86 fair value estimate, 5.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. The price runs 14.1% above the base estimate.
Third-party analyst targets. The average target sits +10% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $39.86, with a range of $39.60 to $45.84, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Chemicals Maker Shows The Classic Cycle Trap
Walk into any factory making plastic parts for cars or packaging and the price of those coloured pellets swings hard with the economy. Avient sits right in that flow, mixing additives and engineered materials that only sell well when demand is strong. At 10.9 times forward earnings the shares look inexpensive next to the analyst target of 47 dollars, yet revenue growth of just 2 percent, a 5 percent profit margin and 7 percent return on equity tell a different story. We pass.
The business clears our ethical screen with no obvious red flags on labour or environment. Margins and returns remain modest even after the recent price dip to 36.97 dollars against our fair value of 37.80, leaving almost no margin of safety. Low growth and thin profitability leave little room for the surprises that usually hit specialty chemical firms.
Because this is a cyclical industry the low multiple is not a bargain but a warning. Peak earnings often coincide with the lowest valuations, and any slowdown in autos or construction could quickly erase the apparent cheapness. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
AVNT trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup$43.25-0.5%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Markup$43.45+1.4%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Markup$42.84+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Markup$42.84+0.0%Entry 15
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Markup$42.84-0.1%Entry 14
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Markup$42.88+1.6%Entry 13
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markup$42.19+4.6%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markup · changed$40.35+0.0%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48.
2026-10-20Markdown$39.00+3.2%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 3% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (7 analysts) rates it buy, with a mean price target of $48.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
